Nektar plummets on lower-than-expected response rates

Nektar Therapeutics (NASDAQ:NKTR) fell $37.78 (42%) to $52.57 Monday after the company said it will start Phase III testing of its NKTR-214 plus anti-PD-1 mAb Opdivo nivolumab based on lower-than-expected Phase I/II response rates reported Saturday at the American Society of Clinical Oncology meeting in Chicago. The

Read the full 477 word article

User Sign In